Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

An2 Therapeutics Inc (ANTX)

An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,206
  • Shares Outstanding, K 35,949
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,170 K
  • EBIT $ -38 M
  • EBITDA $ -39 M
  • 60-Month Beta -1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 1
  • High Estimate $-0.23
  • Low Estimate $-0.23
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +6.03%
on 04/10/26
5.19 -40.75%
on 03/17/26
-1.87 (-37.75%)
since 03/13/26
3-Month
1.00 +207.50%
on 02/19/26
6.91 -55.50%
on 03/09/26
+1.77 (+134.73%)
since 01/14/26
52-Week
1.00 +207.50%
on 02/19/26
6.91 -55.50%
on 03/09/26
+1.77 (+134.73%)
since 04/14/25

Most Recent Stories

More News
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation...

ANTX : 3.01 (unch)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase...

ANTX : 3.01 (unch)
AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered...

ANTX : 3.01 (unch)
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26...

ANTX : 3.01 (unch)
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman,...

ANTX : 3.01 (unch)
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop,...

ANTX : 3.01 (unch)
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) ...

ANTX : 3.01 (unch)
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 awarded third year of funding from Gates Foundation

ANTX : 3.01 (unch)
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that...

ANTX : 3.01 (unch)
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028

ANTX : 3.01 (unch)

Business Summary

AN2 Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. AN2 Therapeutics Inc. is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 3.22
2nd Resistance Point 3.14
1st Resistance Point 3.08
Last Price 3.01
1st Support Level 2.94
2nd Support Level 2.86
3rd Support Level 2.80

See More

52-Week High 6.91
Fibonacci 61.8% 4.65
Fibonacci 50% 3.95
Fibonacci 38.2% 3.26
Last Price 3.01
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.